<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607112464239</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607112464239</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Compatibility of Intravenous Medications With Parenteral Nutrition</article-title>
<subtitle>In Vitro Evaluation</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bouchoud</surname><given-names>Lucie</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607112464239">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fonzo-Christe</surname><given-names>Caroline</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607112464239">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Klingmüller</surname><given-names>Martin</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-0148607112464239">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bonnabry</surname><given-names>Pascal</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607112464239">1</xref>
<xref ref-type="aff" rid="aff3-0148607112464239">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607112464239">
<label>1</label>Service of Pharmacy, Geneva University Hospitals, Geneva, Switzerland</aff>
<aff id="aff2-0148607112464239">
<label>2</label>Ecotox, Oldenburg, Germany</aff>
<aff id="aff3-0148607112464239">
<label>3</label>School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Switzerland</aff>
<author-notes>
<corresp id="corresp1-0148607112464239">Lucie Bouchoud, Service of Pharmacy, Geneva University Hospitals, Gabrielle-Perret-Gentil 4, 1211 Geneva 14, Switzerland. Email: <email>lucie.bouchoud@hcuge.ch</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>37</volume>
<issue>3</issue>
<fpage>416</fpage>
<lpage>424</lpage>
<history>
<date date-type="received">
<day>9</day>
<month>7</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>8</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background and Aim</italic>: Hospitalized patients requiring parenteral nutrition (PN) often need to receive intravenous (IV) medications as well. Y-site administration is occasionally necessary, but physicochemical incompatibilities can occur between the medications and PN. The aim of the present study was to assess the physical compatibility between 25 frequently coadministered IV medications and a commercially available ready-to-use total PN. <italic>Methods</italic>: PN (NuTRIflex Lipid Special; B. Braun Medical AG, Sempach, Switzerland) and medications were mixed in 1:1 (v/v) proportions, and the stability was assessed at the time of mixing and after 1 and 4 hours. The stability of lipid emulsion was observed by microscopic investigation, visual inspection, dynamic laser light scattering, and laser light obscuration. The binary admixtures of PN (without lipid emulsion) and medications were used to detect discoloration, visibly detectable precipitates, and subvisual particles. <italic>Results</italic>: Two of 25 medications were incompatible with the lipid emulsion (serum albumin 20% and tropisetron), 2 showed signs of degradation (discoloration) over time (esomeprazole and pantoprazole), and 1 precipitated at high concentrations (5-fluorouracil). The other 20 medications were considered compatible when administered by Y-site. <italic>Conclusion</italic>: The present study validated the compatibility of 1 commercially available PN and 20 medications. These results offer new solutions to support the implementation of complex therapeutic schemes in practice, when coadministration via Y-site cannot be avoided.</p>
</abstract>
<kwd-group>
<kwd>parenteral nutrition</kwd>
<kwd>administration</kwd>
<kwd>compatibility</kwd>
<kwd>drugs</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607112464239">
<title>Clinical Relevancy Statement</title>
<p>Administering parenteral nutrition (PN) and medications at the Y-site is not recommended but cannot be avoided when a large number of injectable medications have to be coinfused. It is therefore very important to rely on accurate information regarding the compatibility of PN and medications to ensure patient safety. This study evaluated the compatibility of 25 medications with an all-in-one PN. Results can help implement complex therapeutic schemes in the practice.</p>
</sec>
<sec id="section2-0148607112464239" sec-type="intro">
<title>Introduction</title>
<p>Hospitalized patients requiring parenteral nutrition (PN) often receive intravenous (IV) medications as well. In the presence of complex therapeutic schemes, it is sometimes difficult to follow the recommendation of strict avoidance of coadministration at the Y-site of the medications and PN, even if multiple lumen catheters are used. All-in-one solutions constitute the standard for PN, but these are complex admixtures with a high number of chemically reactive components and, moreover, are formulated as a lipid emulsion, which is a thermodynamically unstable form. The physicochemical stability of these admixtures is important for safe infusion practice. Classical physicochemical incompatibilities result in precipitation, emulsion damage, and discoloration of the solution. These reactions may depend on the physicochemical properties of the mixed medications but are also related to cofactors, such as concentration, temperature, light exposure, and the presence of catalysts (trace element). These reactions can lead to catheter occlusion (precipitant), modified bioavailability of the nutrient or medication, and, in the most critical cases, microvascular pulmonary emboli.<sup><xref ref-type="bibr" rid="bibr1-0148607112464239">1</xref></sup> The stability of the emulsion is a critical parameter that needs special analytical methods and equipment. Neither the European nor the Swiss Pharmacopoeias propose droplet size limits for injectable lipid emulsion. On the contrary, the United States Pharmacopeia (USP) provides 2 limits for the globule size distribution: one concerning the mean droplet size (MDS) of the globules, which should not exceed 500 nm, and the other regarding the percentage of the volume of the large-in-diameter tail of the lipid droplet distribution related to the total lipid volume. This proportion is expressed as PFAT<sub>5</sub> (volume of all lipid droplets ≥5 µm), which should not exceed 0.05%<sup><xref ref-type="bibr" rid="bibr2-0148607112464239">2</xref></sup> for pure lipid emulsions for long-term storage. Moreover, the instability of a lipid emulsion is justified as evident when the PFAT<sub>5</sub> exceeds 0.4%.<sup><xref ref-type="bibr" rid="bibr3-0148607112464239">3</xref></sup></p>
<p>To avoid clinical problems resulting from incompatibility between the medications and PN, the European Society of Parenteral and Enteral Nutrition edited an educational paper, which recommends administering the medications intermittently with PN (with sufficient rinsing fluid) when possible and adding the medications via a Y-site connection only if sufficient proof of stability is reported (literature, experimental analyses).<sup><xref ref-type="bibr" rid="bibr4-0148607112464239">4</xref></sup> Some authors evaluated the compatibility between PN and the medications in a static way<sup><xref ref-type="bibr" rid="bibr5-0148607112464239">5</xref><xref ref-type="bibr" rid="bibr6-0148607112464239"/>-<xref ref-type="bibr" rid="bibr7-0148607112464239">7</xref></sup> or by simulating Y-site administration.<sup><xref ref-type="bibr" rid="bibr8-0148607112464239">8</xref></sup> However, literature about the interaction of PN and medications is sparse and sometimes contradictory. In addition, the studies were conducted more than 10 years ago.<sup><xref ref-type="bibr" rid="bibr9-0148607112464239">9</xref>,<xref ref-type="bibr" rid="bibr10-0148607112464239">10</xref></sup> Since that time, the PN technology and medications have evolved. Therefore, the value of such information is limited.</p>
<p>The objective of the present study was to evaluate the physicochemical compatibility of NuTRIflex Lipid special (PN used in our institution; B. Braun Medical AG, Sempach, Switzerland) with 25 medications frequently prescribed to patients under PN. The aim was to generate sufficient data to improve the safety of Y-site administration of medications with the PN. The present study was designed to simulate worst-case conditions with a static contact time between the medications and PN up to 4 hours and was inspired by the method used by Trissel et al.<sup><xref ref-type="bibr" rid="bibr10-0148607112464239">10</xref></sup></p>
</sec>
<sec id="section3-0148607112464239" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section4-0148607112464239">
<title>Selection of the Medications</title>
<p>Nurses responsible for the 12 wards most frequently administering PN in our institution were interviewed by a standardized questionnaire. The nurses were asked about the medications most frequently coadministered with PN and/or the most difficult to manage (ie, administration upon 24 hours or repeated administration). The first 25 medications issued from the interviews were chosen for the study. The concentrations tested were the maximal concentrations recommended for IV administration (internal data; <xref ref-type="table" rid="table1-0148607112464239">Table 1</xref>).</p>
<table-wrap id="table1-0148607112464239" position="float">
<label>Table 1.</label>
<caption>
<p>Medications Tested for Incompatibility With NuTRIflex Lipid Special.</p>
</caption>
<graphic alternate-form-of="table1-0148607112464239" xlink:href="10.1177_0148607112464239-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Medication Substance</th>
<th align="center">Brand Names and Presentation</th>
<th align="center">Manufacturer</th>
<th align="center">Batch No.</th>
<th align="center">Concentration of the Drug Substance Prior to Mixing With NuTRIflex</th>
<th align="center">Diluent/Solvent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td>Albumin fiol 20% CSL</td>
<td>CSL Behring</td>
<td>4307500013</td>
<td>200 mg/mL</td>
<td>Undiluted</td>
</tr>
<tr>
<td>Amoxicillin/Ac. clav.</td>
<td>Co-amoxicilline Sandoz powder 1 g amoxicillin, 0.2 g Ac Clav</td>
<td>Sandoz</td>
<td>147894</td>
<td>50 mg/mL (amoxicillin)</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>10 mg/mL (Ac. clav.)</td>
<td/>
</tr>
<tr>
<td>Calcium chloride</td>
<td>Calcium chlorure amp 75 mg/mL</td>
<td>Internal production</td>
<td>PDS/9-62974</td>
<td>0.13 mmol/mL Ca</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Cefepime</td>
<td>Cefepime Orpha powder 1 g</td>
<td>Orpha Pharma</td>
<td>OPMID8001</td>
<td>100 mg/mL</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Sandimmum sol. 50 mg = 1 mL</td>
<td>Novartis</td>
<td>S0034</td>
<td>2.5 mg/mL</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Esomeprazole</td>
<td>Nexium powder 40 mg</td>
<td>AstraZeneca</td>
<td>KE1688</td>
<td>0.8 mg/mL</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>Synthenyl 0.5 mg = 10 mL</td>
<td>Sintetica-Bioren</td>
<td>10069</td>
<td>0.05 mg/mL</td>
<td>Undiluted</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>Fluoro-uracil TEVA</td>
<td>TEVA Pharma</td>
<td>09A05OB</td>
<td>50 mg/mL</td>
<td>Undiluted</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>Fluoro-uracil TEVA</td>
<td>TEVA Pharma</td>
<td>09A05OB</td>
<td>1.06/3.125/6.25/ 12.5 mg/mL</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Furosemide</td>
<td>Lasix sol. 250 mg = 25 ml</td>
<td>sanofi-aventis</td>
<td>B149</td>
<td>10 mg/mL</td>
<td>Undiluted</td>
</tr>
<tr>
<td>Magnesium sulfate</td>
<td>Magnesium sulfate 10% 10mL</td>
<td>Bichsel AG</td>
<td>A05079</td>
<td>0.4 mmol/mL Mg</td>
<td>Undiluted</td>
</tr>
<tr>
<td>Meropenem</td>
<td>Meronem powder 1 g</td>
<td>AstraZeneca</td>
<td>08288D</td>
<td>50 mg/mL</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>Paspertin amp 10 mg = 2 mL</td>
<td>Abbott Pharma</td>
<td>111647</td>
<td>5 mg/mL</td>
<td>undiluted</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Metronidazole sol. 50 mg = 10 mL</td>
<td>Sintetica-Bioren</td>
<td>08092204</td>
<td>5 mg/mL</td>
<td>undiluted</td>
</tr>
<tr>
<td>Midazolam</td>
<td>Dormicum sol. 50 mg = 10 mL</td>
<td>Roche Pharma</td>
<td>F0013</td>
<td>2.5 mg/mL</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Morphine sulfate</td>
<td>Morphine sulfate fiol 100 mg = 2.5 mL</td>
<td>Sintetica-Bioren</td>
<td>08115082</td>
<td>5 mg/mL</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Noradrenaline</td>
<td>Noradrenaline amp 10 mg = 10 mL</td>
<td>Sintetica-Bioren</td>
<td>09081</td>
<td>1 mg/mL</td>
<td>Undiluted</td>
</tr>
<tr>
<td>Octreotide</td>
<td>Sandostatin sol. 1 mg = 5 mL</td>
<td>Novartis</td>
<td>S0028</td>
<td>25 µg/mL</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>Zofran sol. 8 mg = 4 mL</td>
<td>GlaxoSmithKline</td>
<td>8007</td>
<td>2 mg/mL</td>
<td>Undiluted</td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>Pantozol fiol sec 40 mg</td>
<td>Nycomed Pharma</td>
<td>388756</td>
<td>0.8 mg/mL</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>Perfalgan sol. 1 g = 100 mL</td>
<td>Bristol-Myers Squibb</td>
<td>8G32978</td>
<td>10 mg/mL</td>
<td>undiluted</td>
</tr>
<tr>
<td>Piperacillin/tazobactam</td>
<td>Piperazillin/tazobactam 4 g + 500 mg</td>
<td>TEVA Pharma</td>
<td>AM4262</td>
<td>80 mg/mL (piper.)</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Potassium phosphate</td>
<td>Kaliumphosphat amp 1.36 mg = 10 mL</td>
<td>B. Braun Medical AG</td>
<td>9353C33</td>
<td>0.12 mmol/L PO<sub>4</sub></td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>Prograf amp 5 mg = 1 mL</td>
<td>Astellas Pharma</td>
<td>5A3170G</td>
<td>0.1 mg/mL</td>
<td>NaCl 0.9%</td>
</tr>
<tr>
<td>Tropisetron</td>
<td>Navoban amp 5 mg = 5 mL</td>
<td>Novartis</td>
<td>S0078, S0067</td>
<td>1 mg/mL</td>
<td>Undiluted</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>Vancocin powder 500 mg</td>
<td>TEVA Pharma</td>
<td>8746</td>
<td>10 mg/mL</td>
<td>NaCl 0.9%</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The PN used in the present study was NuTRIflex Lipid special (B. Braun Medical AG), which is a 3-chamber bag with lipid emulsion, amino acid solution/electrolytes, and glucose/electrolytes (<xref ref-type="table" rid="table2-0148607112464239">Table 2</xref>).</p>
<table-wrap id="table2-0148607112464239" position="float">
<label>Table 2.</label>
<caption>
<p>Composition of NuTRIflex Lipid Special (B. Braun Medical).</p>
</caption>
<graphic alternate-form-of="table2-0148607112464239" xlink:href="10.1177_0148607112464239-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Components</th>
<th align="center" colspan="2">Per 1000 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amino acids</td>
<td>57.4</td>
<td>g</td>
</tr>
<tr>
<td>Lipids<sup><xref ref-type="table-fn" rid="table-fn1-0148607112464239">a</xref></sup></td>
<td>40</td>
<td>g</td>
</tr>
<tr>
<td>Glucose</td>
<td>144</td>
<td>g</td>
</tr>
<tr>
<td>Sodium</td>
<td>54</td>
<td>mmol</td>
</tr>
<tr>
<td>Potassium</td>
<td>38</td>
<td>mmol</td>
</tr>
<tr>
<td>Calcium</td>
<td>4.2</td>
<td>mmol</td>
</tr>
<tr>
<td>Magnesium</td>
<td>4.2</td>
<td>mmol</td>
</tr>
<tr>
<td>Phosphate</td>
<td>16</td>
<td>mmol</td>
</tr>
<tr>
<td>Chloride</td>
<td>48</td>
<td>mmol</td>
</tr>
<tr>
<td>Acetate</td>
<td>48</td>
<td>mmol</td>
</tr>
<tr>
<td>Zinc</td>
<td>0.03</td>
<td>mmol</td>
</tr>
<tr>
<td>Osmolarity</td>
<td>2090</td>
<td>mosm/L</td>
</tr>
<tr>
<td>pH</td>
<td>5-6</td>
<td/>
</tr>
<tr>
<td>Batches used</td>
<td>7421A159</td>
<td>EXP 09.2009</td>
</tr>
<tr>
<td/>
<td>8322A154</td>
<td>EXP 07.2010</td>
</tr>
<tr>
<td/>
<td>8424A159</td>
<td>EXP 09.2010</td>
</tr>
<tr>
<td/>
<td>8322A155</td>
<td>EXP 07.2011</td>
</tr>
<tr>
<td/>
<td>9403A152</td>
<td>EXP 08.2011</td>
</tr>
<tr>
<td/>
<td>8322A156</td>
<td>EXP 07.2011</td>
</tr>
<tr>
<td/>
<td>9481A151</td>
<td>EXP 10.2011</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607112464239">
<label>a</label><p>Mix of long-chain triglycerides/medium-chain triglycerides.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-0148607112464239">
<title>Compatibility Tests</title>
<p>Compatibility was evaluated by justification of the stability of lipid emulsions (visual appearance, microscopic images, PFAT<sub>5</sub>, average lipid droplet size) and lipid-free samples (visual appearance, color, turbidity, precipitation, subvisual particle count, pH). Lipid emulsions were ternary PN admixtures (glucose, amino acids, and lipid emulsion plus injectable medication), and lipid-free samples were binary mixtures (glucose and amino acids plus injectable medication).</p>
<p>The admixtures were static admixtures of medication and PN with a ratio of 1:1 (v/v). The PN was prepared (either mixing the content of all 3 chambers of the bag for ternary PN or mixing the chamber with dextrose and amino acids for binary PN) just before the tests.</p>
</sec>
<sec id="section6-0148607112464239">
<title>Preparation of Lipid-Free Samples</title>
<p>Under aseptic and laminar air flow (LAF) conditions, 50 mL of PN (binary) was sampled and transferred to a dry but prewashed (filtrated deionized water) 100-mL glass bottle. Then, 50 mL of medication solution was added to PN. Medications needing a reconstitution step were mixed to PN after complete solubilization of the powder (visually detected). The container was closed with a prewashed (filtrated deionized water) rubber stopper, and the content was mixed by shaking. Compatibility tests were performed on duplicate samples at the time of mixing (T0) and after 1 (T1) and 4 (T4) hours of contact. The samples were stored at room temperature and in daylight in the laboratory.</p>
</sec>
<sec id="section7-0148607112464239">
<title>Preparation of Lipid-Containing Samples</title>
<p>Under aseptic and LAF conditions, 75 mL of PN (ternary) was sampled and transferred to a 500-mL EVA bag (Nutrimix; B. Braun Medical AG). Then, 75 mL of medication solution was added to PN. Medications needing a reconstitution step were mixed to PN after complete solubilization of the powder (visually detected). The container was closed with a clamp and cap, and the content was mixed by shaking. Compatibility tests were performed on duplicate samples at the time of mixing (T0) and after 1 (T1) and 4 (T4) hours of contact. The samples were stored at room temperature and in daylight in the laboratory. Samples were drawn from the container at test points using an Omnifix syringe (50 mL) and a MiniSpike V via the infusion port of the container (B. Braun Medical AG).</p>
</sec>
<sec id="section8-0148607112464239">
<title>Test Methods and Acceptance Criteria for Lipid Emulsion Stability</title>
<p>At each test point, the samples were inspected visually for obvious deterioration of the emulsion and/or oil separation. The pH (WTW pH 3310 with a Sentix [GmbH, Weilheim, Germany] 41 electrode) was measured and a light microscopic investigation of the lipid emulsion was done (Olympus CX 41 [Olympus, Center Valley, PA]; 5-µL emulsion was visually investigated in the dark field at an enlargement factor of 400). Furthermore, mean lipid droplet size distribution was determined by dynamic light scattering (Nicomp 380; Particle Sizing Systems, Santa Barbara, CA). PFAT<sub>5</sub> was tested by light obscuration (Accusizer 780/APS; Particle Sizing Systems Santa Barbara, CA).</p>
<p>To be considered compatible, the following criteria had to be met:</p>
<list id="list1-0148607112464239" list-type="simple">
<list-item><p><italic>Visual inspection not conspicuous, no oil separation, no phase separation</italic>. An emulsion presenting a deterioration of the emulsion on visual inspection, which cannot be reemulsified any more, is not acceptable.</p></list-item>
<list-item><p><italic>Change in pH value ≤0.2 over the evaluation period</italic>. Limits for the pH value include possible hydrolysis of ingredients, which could result in a detectable pH shift.</p></list-item>
<list-item><p><italic>No lipid droplets &gt;15 µm visible in 5 microscopic images, not more than 90 lipid droplets from 2–15 µm in size in 5 microscopic images</italic>. An emulsion presenting great lipid droplets under the microscope exceeding the defined limits can be justified as significantly damaged.</p></list-item>
<list-item><p><italic>Average lipid droplet size from 200–350 nm, less than 10% change over the evaluation period</italic>. The average droplet size depends on the product specification. A significant change of the droplet size upon storage indicates a severe change of the emulsion quality.</p></list-item>
<list-item><p><italic>PFAT<sub>5</sub> &lt;0.4%</italic>. A PFAT<sub>5</sub> of 0.4% is seen as an acceptance limit for a stable emulsion upon short-term storage.</p></list-item></list>
</sec>
<sec id="section9-0148607112464239">
<title>Test Methods and Acceptance Criteria for Lipid-Free Admixtures</title>
<p>At each time of analysis, the samples were visually inspected against a black-and-white contrast background for evidence of visible particles or precipitation following the method described in the European Pharmacopeia (Eur. Ph.) chapter 2.9.20.</p>
<p>Subvisual particles were counted in clear samples as described in the Eur. Ph. chapter 2.9.1 with a Hiac/Royco 90/64 laser light extinction particle counter (Pacific Scientific, USA) placed in a horizontal laminar airflow hood to avoid particle contamination. Four test runs of each 5-mL sample were done, but particle counts were assessed by the average of the 3 last counts.</p>
<p>Color of the samples was tested a colorimeter (LICO 400; Hach Lange, Düsseldorf, Germany), which was calibrated to the standard solutions presented in Eur. Ph. chapter 2.2.2. The samples were automatically compared with the color index of the European Pharmacopeia.</p>
<p>To be considered as compatible, the following criteria had to be met:</p>
<list id="list2-0148607112464239" list-type="simple"><list-item><p>Practically free from visible particles; no turbidity or precipitation may be detected upon visual inspection. These criteria follow the requirements of the European Pharmacopoeia for parenterals.</p></list-item>
<list-item><p>Not more than 25 particles ≥10 µm/mL and not more than 3 particles ≥25 µm/mL. These criteria follow the requirements of the European Pharmacopoeia for parenterals at a container size of more than 100 mL. If the particle counts were above the Eur. Ph. limits, the medication solution was diluted 1:1 with NaCl 0.9% and was tested for subvisual particles to determine if the result was a consequence of an incompatibility or if the medication itself was contaminated with particles. This was particularly important for medications that needed a reconstitution step.</p></list-item>
<list-item><p>Change of color not more than 1 degree. This criterion reflects the precision of the test method. If a discoloration occurs, this may be related to a change in the medication activity. If the color changed, that discoloration was compared with a mixture of NaCl/medication solution to evaluate the extent of discoloration due to the medication independently of contact with the PN.</p></list-item></list>
<p>The tests on ternary PN were done in the independent laboratory Ecotox (Germany), and the tests on binary PN were done at the Pharmacy of the Geneva University Hospitals.</p>
</sec></sec>
<sec id="section10-0148607112464239" sec-type="results">
<title>Results</title>
<sec id="section11-0148607112464239">
<title>Tests on Lipid Emulsion</title>
<p>Twenty-three of the 25 medication/PN combinations met the specification for the lipid emulsion, whereas 2 did not (serum albumin 20% and tropisetron; <xref ref-type="table" rid="table3-0148607112464239">Table 3</xref>). Serum albumin 20% added to PN presented a phase separation after 10 minutes. PFAT<sub>5</sub> of tropisetron samples was elevated (&gt;0.6%) starting from T0, but no sign of phase separation was visible (<xref ref-type="table" rid="table4-0148607112464239">Tables 4</xref> and <xref ref-type="table" rid="table5-0148607112464239">5</xref>). The pH of the mixtures was stable within ±0.05 pH units over time, except for the mixtures containing amoxicillin, which presented pH values of 7.9 at T0, 7.8 at T1, and 7.6 at T4 (<xref ref-type="table" rid="table3-0148607112464239">Table 3</xref>). The average droplet sizes remained stable around 300 nm in all samples (<xref ref-type="table" rid="table6-0148607112464239">Table 6</xref>) throughout the overall study period (minimum 282 nm, maximum 312 nm).</p>
<table-wrap id="table3-0148607112464239" position="float">
<label>Table 3.</label>
<caption>
<p>Mean Volume-Weighted Percentage of Fat &gt;5 µm (PFAT<sub>5</sub>) and pH of Samples.</p>
</caption>
<graphic alternate-form-of="table3-0148607112464239" xlink:href="10.1177_0148607112464239-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3">PFAT<sub>5</sub>, % (Limit &lt;0.4%)<hr/></th>
<th align="center" colspan="2">pH Limit: Change During Storage &lt;0.2 Units<hr/></th>
</tr>
<tr>
<th align="left">Medication Substance</th>
<th align="center">T0</th>
<th align="center">T1</th>
<th align="center">T4</th>
<th align="center">T0</th>
<th align="center">T4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td colspan="3">Phase separation</td>
<td>6.3</td>
<td>6.3</td>
</tr>
<tr>
<td>Amoxicillin/Ac. clav.</td>
<td>0.05</td>
<td>0.03</td>
<td>0.03</td>
<td>7.9</td>
<td>7.6</td>
</tr>
<tr>
<td>Calcium chloride</td>
<td>0.02</td>
<td>0.02</td>
<td>0.01</td>
<td>5.4</td>
<td>5.4</td>
</tr>
<tr>
<td>Cefepime</td>
<td>0.03</td>
<td>0.01</td>
<td>0.01</td>
<td>4.9</td>
<td>4.9</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>0.04</td>
<td>0.03</td>
<td>0.03</td>
<td>5.6</td>
<td>5.6</td>
</tr>
<tr>
<td>Esomeprazole</td>
<td>0.02</td>
<td>0.02</td>
<td>0.02</td>
<td>5.7</td>
<td>5.7</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>0.03</td>
<td>0.05</td>
<td>0.07</td>
<td>5.5</td>
<td>5.5</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>0.04</td>
<td>0.04</td>
<td>0.04</td>
<td>8.3</td>
<td>8.3</td>
</tr>
<tr>
<td>Furosemide</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
<td>5.7</td>
<td>5.7</td>
</tr>
<tr>
<td>Magnesium sulfate</td>
<td>0.02</td>
<td>0.02</td>
<td>0.02</td>
<td>5.3</td>
<td>5.3</td>
</tr>
<tr>
<td>Meropenem</td>
<td>0.07</td>
<td>0.04</td>
<td>0.09</td>
<td>7.3</td>
<td>7.3</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>0.03</td>
<td>0.03</td>
<td>0.02</td>
<td>5.5</td>
<td>5.5</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>0.02</td>
<td>0.01</td>
<td>0.02</td>
<td>5.5</td>
<td>5.5</td>
</tr>
<tr>
<td>Midazolam</td>
<td>0.06</td>
<td>0.05</td>
<td>0.05</td>
<td>5.3</td>
<td>5.3</td>
</tr>
<tr>
<td>Morphine sulfate</td>
<td>0.03</td>
<td>0.05</td>
<td>0.14</td>
<td>5.5</td>
<td>5.5</td>
</tr>
<tr>
<td>Noradrenaline</td>
<td>0.04</td>
<td>0.02</td>
<td>0.04</td>
<td>5.2</td>
<td>5.2</td>
</tr>
<tr>
<td>Octreotide</td>
<td>0.02</td>
<td>0.02</td>
<td>0.04</td>
<td>5.5</td>
<td>5.5</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>0.1</td>
<td>0.05</td>
<td>0.03</td>
<td>5.3</td>
<td>5.3</td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>0.15</td>
<td>0.1</td>
<td>0.09</td>
<td>5.6</td>
<td>5.6</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>0.03</td>
<td>0.02</td>
<td>0.03</td>
<td>5.6</td>
<td>5.6</td>
</tr>
<tr>
<td>Piperacillin/tazobactam</td>
<td>0.14</td>
<td>0.25</td>
<td>0.11</td>
<td>5.6</td>
<td>5.6</td>
</tr>
<tr>
<td>Potassium phosphate</td>
<td>0.05</td>
<td>0.03</td>
<td>0.03</td>
<td>5.3</td>
<td>5.3</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>0.16</td>
<td>0.11</td>
<td>0.09</td>
<td>5.5</td>
<td>5.5</td>
</tr>
<tr>
<td>Tropisetron</td>
<td><bold>0.5</bold></td>
<td><bold>1.41</bold></td>
<td><bold>0.42</bold></td>
<td>5.3</td>
<td>5.3</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>0.05</td>
<td>0.05</td>
<td>0.06</td>
<td>5.5</td>
<td>5.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0148607112464239"><p>Bold indicates data that are over specifications.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0148607112464239" position="float">
<label>Table 4.</label>
<caption>
<p>Microscopic Investigation of Lipid Droplets in Samples and Visual Inspection.</p>
</caption>
<graphic alternate-form-of="table4-0148607112464239" xlink:href="10.1177_0148607112464239-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="6">Number of Lipid Droplets Visible in 5 Microscopic Images (400-fold Magnification, 5-µL Sample)<sup><xref ref-type="table-fn" rid="table-fn3-0148607112464239">a</xref></sup><hr/></th>
</tr>
<tr>
<th/>
<th align="center" colspan="2">T0<hr/></th>
<th align="center" colspan="2">T1<hr/></th>
<th align="center" colspan="2">T4<hr/></th>
</tr>
<tr>
<th align="left">Medication Substance</th>
<th align="center">2–15 µm</th>
<th align="center">&gt;15 µm</th>
<th align="center">2–15 µm</th>
<th align="center">&gt;15 µm</th>
<th align="center">2–15 µm</th>
<th align="center">&gt;15 µm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td colspan="2">Agglomerates</td>
<td colspan="2">Agglomerates</td>
<td colspan="2">Agglomerates</td>
</tr>
<tr>
<td>Amoxicillin/Ac. clav.</td>
<td>34</td>
<td>0</td>
<td>35</td>
<td>0</td>
<td>35</td>
<td>0</td>
</tr>
<tr>
<td>Calcium chloride</td>
<td>16</td>
<td>0</td>
<td>15</td>
<td>0</td>
<td>22</td>
<td>0</td>
</tr>
<tr>
<td>Cefepime</td>
<td>23</td>
<td>0</td>
<td>34</td>
<td>0</td>
<td>24</td>
<td>0</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>38</td>
<td>0</td>
<td>40</td>
<td>0</td>
<td>38</td>
<td>0</td>
</tr>
<tr>
<td>Esomeprazole</td>
<td>35</td>
<td>0</td>
<td>49</td>
<td>0</td>
<td>36</td>
<td>0</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>16</td>
<td>0</td>
<td>24</td>
<td>0</td>
<td>28</td>
<td>0</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>15</td>
<td>0</td>
<td>14</td>
<td>0</td>
<td>17</td>
<td>0</td>
</tr>
<tr>
<td>Furosemide</td>
<td>18</td>
<td>0</td>
<td>41</td>
<td>0</td>
<td>26</td>
<td>0</td>
</tr>
<tr>
<td>Magnesium sulfate</td>
<td>15</td>
<td>0</td>
<td>26</td>
<td>0</td>
<td>19</td>
<td>0</td>
</tr>
<tr>
<td>Meropenem</td>
<td>34</td>
<td>0</td>
<td>33</td>
<td>0</td>
<td>40</td>
<td>0</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>21</td>
<td>0</td>
<td>33</td>
<td>0</td>
<td>26</td>
<td>0</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>24</td>
<td>0</td>
<td>28</td>
<td>0</td>
<td>17</td>
<td>0</td>
</tr>
<tr>
<td>Midazolam</td>
<td>44</td>
<td>0</td>
<td>50</td>
<td>0</td>
<td>39</td>
<td>0</td>
</tr>
<tr>
<td>Morphine sulfate</td>
<td>13</td>
<td>0</td>
<td>21</td>
<td>0</td>
<td>28</td>
<td>0</td>
</tr>
<tr>
<td>Noradrenaline</td>
<td>19</td>
<td>0</td>
<td>19</td>
<td>0</td>
<td>22</td>
<td>0</td>
</tr>
<tr>
<td>Octreotide</td>
<td>29</td>
<td>0</td>
<td>45</td>
<td>0</td>
<td>45</td>
<td>0</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>46</td>
<td>0</td>
<td>35</td>
<td>0</td>
<td>53</td>
<td>0</td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>42</td>
<td>0</td>
<td>54</td>
<td>0</td>
<td>62</td>
<td>0</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>40</td>
<td>0</td>
<td>67</td>
<td>0</td>
<td>38</td>
<td>0</td>
</tr>
<tr>
<td>Piperacillin/tazobactam</td>
<td>22</td>
<td>0</td>
<td>25</td>
<td>0</td>
<td>24</td>
<td>0</td>
</tr>
<tr>
<td>Potassium phosphate</td>
<td>28</td>
<td>0</td>
<td>22</td>
<td>0</td>
<td>35</td>
<td>0</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>43</td>
<td>0</td>
<td>53</td>
<td>0</td>
<td>56</td>
<td>0</td>
</tr>
<tr>
<td>Tropisetron</td>
<td>19</td>
<td>0</td>
<td>19</td>
<td>0</td>
<td>23</td>
<td>0</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>23</td>
<td>0</td>
<td>50</td>
<td>0</td>
<td>32</td>
<td>0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0148607112464239">
<label>a</label><p>Limit: no lipid droplet &gt;15 µm, maximum 90 droplets 2–15 µm.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-0148607112464239">
<title>Tests on Lipid-Free Admixtures</title>
<p>Precipitation was visually detected only in the samples containing 5-fluorouracil. The precipitation increased over time from a slight haze at T0 to a dense white precipitate at T4.</p>
<p>Additional tests had been initiated with 5-fluorouracil solution diluted with sodium chloride solution 0.9% to 25 mg/mL, 12.5 mg/mL, 6.25 mg/mL, 3.125 mg/mL, and 1.06 mg/mL, and these dilutions were mixed with NuTRIflex Lipid Special (binary admixtures) (1:1 v + v). The admixture prepared with 25 mg/mL 5-fluoruracil presented visible turbidity after 30 minutes of contact time. All other samples remained visibly clear, and the particles counts met the specification (<xref ref-type="table" rid="table5-0148607112464239">Tables 5</xref> and <xref ref-type="table" rid="table7-0148607112464239">7</xref>).</p>
<table-wrap id="table5-0148607112464239" position="float">
<label>Table 5.</label>
<caption>
<p>Visual Inspection.</p>
</caption>
<graphic alternate-form-of="table5-0148607112464239" xlink:href="10.1177_0148607112464239-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="6">Visual Inspection of Emulsions (Appearance) Visual Inspection of Lipid-Free Samples (Appearance, Particles, Color)<hr/></th>
</tr>
<tr>
<th/>
<th align="center" colspan="3">Requirements: Not Conspicuous, No Oil Separation, No Phase Separation<hr/></th>
<th align="center" colspan="3">Requirements: Practically Free From Visible Particles, No Turbidity or Precipitation, Change of Color Not &gt;1 Degree<hr/></th>
</tr>
<tr>
<th align="left">Medications</th>
<th align="center">T0</th>
<th align="center">T1</th>
<th align="center">T4</th>
<th align="center">T0</th>
<th align="center">T1</th>
<th align="center">T4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td colspan="3">Phase separation</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Amoxicillin/Ac. clav.</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td colspan="2">Increasing discoloration (brown)</td>
</tr>
<tr>
<td>Calcium chloride</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Cefepime</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td colspan="2">Increasing discoloration (brown)</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Esomeprazole</td>
<td colspan="3">Increasing discoloration (purple)</td>
<td colspan="3">Increasing discoloration (brown)</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td colspan="3">Precipitate</td>
</tr>
<tr>
<td>Furosemide</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Magnesium sulfate</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Meropenem</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Midazolam</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Morphine sulfate</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Noradrenaline</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Octreotide</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Pantoprazole</td>
<td colspan="3">Increasing discoloration (brown)</td>
<td colspan="3">Increasing discoloration (brown)</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Piperacillin/tazobactam</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Potassium phosphate</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Tropisetron</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0148607112464239"><p>C, compliant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table6-0148607112464239" position="float">
<label>Table 6.</label>
<caption>
<p>Mean Diameter Size (MDS) of Lipid Droplets in Samples.</p>
</caption>
<graphic alternate-form-of="table6-0148607112464239" xlink:href="10.1177_0148607112464239-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3">MDS, nm (Limits 200–350 nm)<hr/></th>
</tr>
<tr>
<th align="left">Medications</th>
<th align="center">T0</th>
<th align="center">T1</th>
<th align="center">T4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td colspan="3">Phase separation</td>
</tr>
<tr>
<td>Amoxicillin/Ac. clav.</td>
<td>293</td>
<td>289</td>
<td>289</td>
</tr>
<tr>
<td>Calcium chloride</td>
<td>300</td>
<td>300</td>
<td>300</td>
</tr>
<tr>
<td>Cefepime</td>
<td>293</td>
<td>292</td>
<td>289</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>295</td>
<td>293</td>
<td>292</td>
</tr>
<tr>
<td>Esomeprazole</td>
<td>291</td>
<td>290</td>
<td>290</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>310</td>
<td>306</td>
<td>307</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>299</td>
<td>299</td>
<td>300</td>
</tr>
<tr>
<td>Furosemide</td>
<td>286</td>
<td>285</td>
<td>282</td>
</tr>
<tr>
<td>Magnesium sulfate</td>
<td>300</td>
<td>302</td>
<td>303</td>
</tr>
<tr>
<td>Meropenem</td>
<td>292</td>
<td>292</td>
<td>291</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>299</td>
<td>299</td>
<td>298</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>289</td>
<td>290</td>
<td>288</td>
</tr>
<tr>
<td>Midazolam</td>
<td>285</td>
<td>287</td>
<td>286</td>
</tr>
<tr>
<td>Morphine sulfate</td>
<td>311</td>
<td>308</td>
<td>305</td>
</tr>
<tr>
<td>Noradrenaline</td>
<td>297</td>
<td>297</td>
<td>297</td>
</tr>
<tr>
<td>Octreotide</td>
<td>292</td>
<td>292</td>
<td>288</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>290</td>
<td>288</td>
<td>287</td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>302</td>
<td>299</td>
<td>298</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>290</td>
<td>289</td>
<td>288</td>
</tr>
<tr>
<td>Piperacillin/tazobactam</td>
<td>300</td>
<td>299</td>
<td>297</td>
</tr>
<tr>
<td>Potassium phosphate</td>
<td>299</td>
<td>295</td>
<td>300</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>303</td>
<td>303</td>
<td>303</td>
</tr>
<tr>
<td>Tropisetron</td>
<td>299</td>
<td>298</td>
<td>297</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>288</td>
<td>288</td>
<td>296</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table7-0148607112464239" position="float">
<label>Table 7.</label>
<caption>
<p>Particle Counts in Samples.</p>
</caption>
<graphic alternate-form-of="table7-0148607112464239" xlink:href="10.1177_0148607112464239-table7.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Medications</th>
<th align="center" colspan="3">Particles/mL ≥10 µm<hr/></th>
<th align="center" colspan="3">Particles/mL ≥25 µm<hr/></th>
</tr>
<tr>
<th/>
<th align="center">T0</th>
<th align="center">T1</th>
<th align="center">T4</th>
<th align="center">T0</th>
<th align="center">T1</th>
<th align="center">T4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td>10</td>
<td>11</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Amoxicillin/Ac. clav.</td>
<td>60</td>
<td>53</td>
<td>66</td>
<td>5</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Calcium chloride</td>
<td>8</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cefepime</td>
<td>56</td>
<td>42</td>
<td>31</td>
<td>5</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>366</td>
<td>344</td>
<td>218</td>
<td>15</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Esomeprazole</td>
<td>9</td>
<td>6</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>11</td>
<td>9</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fluorouracil 50 mg/mL</td>
<td/>
<td>Turbidity</td>
<td/>
<td/>
<td>Turbidity</td>
<td/>
</tr>
<tr>
<td>Fluorouracil 25 mg/mL</td>
<td/>
<td>Turbidity</td>
<td/>
<td/>
<td>Turbidity</td>
<td/>
</tr>
<tr>
<td>Fluorouracil 12.5 mg/mL</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Fluorouracil 6.25 mg/mL</td>
<td>9</td>
<td>6</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Fluorouracil 3.125 mg/mL</td>
<td>9</td>
<td>5</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fluorouracil 1.06 mg/mL</td>
<td>7</td>
<td>5</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Furosemide</td>
<td>14</td>
<td>5</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Magnesium sulfate</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Meropenem</td>
<td>121</td>
<td>75</td>
<td>11</td>
<td>8</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>16</td>
<td>20</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Midazolam</td>
<td>15</td>
<td>12</td>
<td>5</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Morphine sulfate</td>
<td>33</td>
<td>37</td>
<td>31</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Noradrenaline</td>
<td>19</td>
<td>14</td>
<td>12</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Octreotide</td>
<td>9</td>
<td>7</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>7</td>
<td>6</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>18</td>
<td>12</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>8</td>
<td>6</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Piperacillin/tazobactam</td>
<td>186</td>
<td>91</td>
<td>44</td>
<td>28</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Potassium phosphate</td>
<td>11</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>62</td>
<td>47</td>
<td>30</td>
<td>11</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Tropisetron</td>
<td>5</td>
<td>9</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>110</td>
<td>74</td>
<td>19</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0148607112464239"><p>Limits for volumes ≤100 mL: 6000 part/container ≥10 µm and 600 part/container ≥25 µm. Limits for volumes &gt;100 mL: 25 part/mL ≥10 µm and 3 part/mL ≥25 µm.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table8-0148607112464239" position="float">
<label>Table 8.</label>
<caption>
<p>Overall Physicochemical Compatibility Data of the 25 Tested Admixtures.</p>
</caption>
<graphic alternate-form-of="table8-0148607112464239" xlink:href="10.1177_0148607112464239-table8.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Medications</th>
<th align="center">Tested Concentrations</th>
<th align="center">Contact 1:1 Compatibility With PN After 1 h</th>
<th align="center">Contact 1:1 Compatibility With PN After 4 h</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Albumin</bold></td>
<td><bold>200 mg/mL</bold></td>
<td><bold>I</bold></td>
<td><bold>I</bold></td>
</tr>
<tr>
<td>Amoxicillin/Ac. clav.</td>
<td>50 mg/mL (amoxicillin)</td>
<td>C</td>
<td><bold>I</bold></td>
</tr>
<tr>
<td/>
<td>10 mg/mL (Ac. clav.)</td>
<td/>
<td/>
</tr>
<tr>
<td>Calcium chloride</td>
<td>0.13 mmol/mL Ca</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Cefepime</td>
<td>100 mg/mL</td>
<td>C</td>
<td><bold>I</bold></td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>2.5 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td><bold>Esomeprazole</bold></td>
<td><bold>0.8 mg/mL</bold></td>
<td><bold>I</bold></td>
<td><bold>I</bold></td>
</tr>
<tr>
<td>Fentanyl</td>
<td>0.05 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>25 and 50 mg/mL</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>≤12.5 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Furosemide</td>
<td>10 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Magnesium sulfate</td>
<td>0.4 mmol/mL Mg</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Meropenem</td>
<td>50 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>5 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>5 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Midazolam</td>
<td>2.5 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Morphine sulfate</td>
<td>5 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Noradrenaline</td>
<td>1 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Octreotide</td>
<td>25 µg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>2 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td><bold>Pantoprazole</bold></td>
<td><bold>0.8 mg/mL</bold></td>
<td><bold>I</bold></td>
<td><bold>I</bold></td>
</tr>
<tr>
<td>Paracetamol</td>
<td>10 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Piperacillin/tazobactam</td>
<td>80 mg/mL (piperacillin)</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Potassium phosphate</td>
<td>0.12 mmol/L PO<sub>4</sub></td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>0.1 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
<tr>
<td><bold>Tropisetron</bold></td>
<td><bold>1 mg/mL</bold></td>
<td><bold>I</bold></td>
<td><bold>I</bold></td>
</tr>
<tr>
<td>Vancomycin</td>
<td>10 mg/mL</td>
<td>C</td>
<td>C</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0148607112464239"><p>C, compatible; I, incompatible; PN, parenteral nutrition. Bold used to enhance incompatible medications.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The reconstituted medications (amoxicillin/clavulanic acid, cefepime, and meropenem) and the solutions of morphine, cyclosporine, and tacrolimus presented particle counts above the defined limits for high-volume parenterals (volume &gt;100 mL), both when they were mixed with PN and NaCl 0.9%. The particle counts tended to decrease over time (<xref ref-type="table" rid="table5-0148607112464239">Tables 5</xref> and <xref ref-type="table" rid="table7-0148607112464239">7</xref>).</p>
<p>Four medications (amoxicillin/clavulanic acid, cefepime, esomeprazole, and pantoprazole) presented discoloration. The degree of discoloration of amoxicillin/clavulanic acid and cefepime admixtures with PN was similar for up to a 1-hour contact time (T1, pale yellow) compared with the medication dilutions with sodium chloride 0.9%, but it was greater at the 4-hour contact time in the mixture medication/PN. For esomeprazole and pantoprazole, a brown color appeared at T1 and remained until T4 only when the medication had been mixed with PN but not in medication dilutions with NaCl 0.9% (<xref ref-type="table" rid="table5-0148607112464239">Table 5</xref>).</p>
</sec></sec>
<sec id="section13-0148607112464239" sec-type="discussion">
<title>Discussion</title>
<p>The aim of the present study was to determine the compatibility of the PN used in our institution and 25 frequently coadministered medications.</p>
<p>An increase in the PFAT<sub>5</sub> is the most relevant parameter to determine a destabilization of an injectable lipid emulsion. However, there is a discussion on the limit to apply: the USP specification with a PFAT<sub>5</sub> &lt;0.05% for long-term storage or the &lt;0.4% used by the pharmaceutical industry for compatibility justification upon short-term storage. The second limit was chosen, because commercialized native PN in Europe presented PFAT<sub>5</sub> between 0.05% and 0.23%,<sup><xref ref-type="bibr" rid="bibr11-0148607112464239">11</xref>,<xref ref-type="bibr" rid="bibr12-0148607112464239">12</xref></sup> and the goal of the presented tests is the justification of the physicochemical compatibility of medication/emulsion admixtures. Second, there is no proof of clinical damage of administering lipid emulsion with PFAT<sub>5</sub> &lt;0.4%. Some animal studies indicate possible liver injury with unstable emulsions,<sup><xref ref-type="bibr" rid="bibr13-0148607112464239">13</xref><xref ref-type="bibr" rid="bibr14-0148607112464239"/>-<xref ref-type="bibr" rid="bibr15-0148607112464239">15</xref></sup> but only a PFAT<sub>5</sub> &gt;0.4% during infusion appears to be clearly correlated with hepatic injury.<sup><xref ref-type="bibr" rid="bibr16-0148607112464239">16</xref></sup> Thus, for the present study, it was decided that if PFAT<sub>5</sub> increased over time and exceeded 0.4%, the medication was declared to be incompatible with PN.</p>
<p>Two medications were incompatible with the emulsion. A phase separation was observed with serum albumin 20% a few minutes after mixing. This finding is in accordance with another study, which indicated destabilization of emulsion when concentrated serum albumin 20% was added to PN.<sup><xref ref-type="bibr" rid="bibr17-0148607112464239">17</xref></sup> Tropisetron showed an increasing PFAT<sub>5</sub> beyond the pharmaceutical limit even at T0, without any change observed visually. In conclusion, both medications were considered incompatible.</p>
<p>Discoloration was observed over time in the NuTRIflex Lipid special samples with esomeprazole or pantoprazole. These findings were different from those observed in medication dilutions with NaCl 0.9%. This color change was considered an indicator of an incompatibility between the proton pump inhibitors (PPIs) and PN. Thus, these medications were determined to be incompatible. It is well known that PPIs are prone to degradation in an acidic solution.<sup><xref ref-type="bibr" rid="bibr18-0148607112464239">18</xref></sup> Therefore, these findings are in accordance with the expectation since the pH of the medication/PN admixtures is around 5.5. Under these conditions, pantoprazole is more stable than esomeprazole.<sup><xref ref-type="bibr" rid="bibr18-0148607112464239">18</xref></sup> However, in the present study, both PPIs showed signs of degradation. Conversely, cefepime and amoxicillin/clavulanic acid were considered compatible, as the discoloration of the medication/PN admixtures also appeared in the medication dilutions with NaCl 0.9%. The observed phenomenon is not an incompatibility issue but is related to some degree of degradation of the medications that occurs independently from the solvent. The compatibility was validated only for 1 hour, because the reconstituted medications should be infused within 30–60 minutes according to the manufacturers’ official recommendations.<sup><xref ref-type="bibr" rid="bibr18-0148607112464239">18</xref></sup> It is stated by the manufacturer that a slight discoloration during that time has no influence on the medications’ activity.</p>
<p>Precipitation was detected only in admixtures of PN and 5-fluorouracil (5-FU). This is related to the poor solubility of that medication substance at pH values &lt;7. To increase the 5-FU solubility, the medication substance is dissolved in sodium hydroxide solution for pharmaceutical preparations, resulting in pH values of approximately 9. Although the final pH of PN/5-FU was still basic (pH 8.3), the solubility was obviously decreased, which resulted in precipitation. Thus, 5-FU was determined to be incompatible with this PN. Nevertheless, the concomitant administration of PN and fluorouracil over several days is often necessary in cancer patients. Precipitation could be avoided by diluting 5-FU with sodium chloride to a concentration of 12.5 mg/mL or less. However, the obtained results point to a possible risk when administering 5-FU and PN at the Y-site. Separated administration through different lines is recommended if the 5-FU concentration is above 12.5 mg/mL.</p>
<p>In some situations, the particle count was above the Eur. Ph. limits for volumes ≥100 mL. This was observed in reconstituted medications as well as in the morphine, cyclosporine, and tacrolimus solutions. The 2 latest medications contain castor oil, which is used for solubilization. As an emulsifying agent, castor oil is also prone to form bubbles, which could be counted as particles erroneously. For lyophilized medications, the number of particles decreased over the test period, indicating that a certain time is needed for a complete solubilization of the medication and suggesting that this was not related to an incompatibility with the PN. For the immunosuppressive medications and morphine, tests were repeated with medication dilutions mixed with NaCl 0.9% instead of PN. An identical number of particles were found. This suggested that the particle counts were due to the formulation itself and not to an incompatibility with PN. Therefore, all these medications were considered compatible. <xref ref-type="table" rid="table8-0148607112464239">Table 8</xref> gives an overview of the compatibiliy data discussed.</p>
<p>The major limitation of the present study is that the results are based on physical reactions, and the medication concentration was not determined. Second, the results are related to the PN as it is obtained with no further additions, such as vitamins or trace elements, and an extrapolation to other commercialized PN should be made with caution. However, incompatible medications (such as fluorouracil or albumin) must be avoided regardless of the brand name used. Finally, the particle counts and precipitates were evaluated in binary PN, which does not present the same pharmaceutical composition as the ternary PN. However, a turbidity caused by the medication addition can only be detected in lipid-free samples. The ternary PN samples were observed visually and microscopically and the droplet size was measured. We assumed that if an insoluble precipitate had occurred in the ternary PN (and not in the binary PN), it would have been detected during these measurements.</p>
<p>The present study confirms some data already published for serum albumin 20% and provides some new data. These results may help healthcare professionals decide whether a Y-site administration of medications and PN with NuTRIflex Lipid special is possible. This information may help to implement complex therapeutic schemes in practice, when coadministration via the Y-site is unavoidable. However, results are valid only for the medication concentrations tested, as this parameter is an important factor for pharmaceutical stability and compatibility.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="presented-at">
<p>A part of this work was presented as an oral communication in November 2009 at the 26th Congress of the Société Francophone Nutrition Clinique et Métabolisme (SFNEP) in Clermont-Ferrand, France.</p></fn>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: The study was financially supported by B. Braun Medical AG, Switzerland.</p></fn>
<fn fn-type="other">
<p>This article originally appeared online on October 30, 2012.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607112464239">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hill</surname><given-names>SE</given-names></name>
<name><surname>Heldman</surname><given-names>LS</given-names></name>
<name><surname>Goo</surname><given-names>ED</given-names></name><etal/>
</person-group>. <article-title>Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1996</year>;<volume>20</volume>:<fpage>81</fpage>-<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr2-0148607112464239">
<label>2.</label>
<citation citation-type="book">
<article-title>Globule size distribution in lipid injectable emulsions</article-title>. Chapter &lt;729&gt;. In: <source>United States Pharmacopeia 31/National Formulary 26</source>. Vol <volume>1</volume>. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>United States Pharmacopeial Convention</publisher-name>; <year>2008</year>:<fpage>285</fpage>-<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr3-0148607112464239">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Driscoll</surname><given-names>DF</given-names></name>
<name><surname>Bhargava</surname><given-names>HN</given-names></name>
<name><surname>Li</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Physicochemical stability of total nutrient admixtures</article-title>. <source>Am J Health Syst Pharm</source>. <year>1995</year>;<volume>52</volume>:<fpage>623</fpage>-<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr4-0148607112464239">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mühlebach</surname><given-names>S</given-names></name>
</person-group>. <article-title>Basics in clinical nutrition: drugs and nutritional admixtures</article-title>. <source>Clin Nutr Metab</source>. <year>2009</year>;<volume>4</volume>:<fpage>e134</fpage>-<lpage>e136</lpage>.</citation>
</ref>
<ref id="bibr5-0148607112464239">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Husson</surname><given-names>E</given-names></name>
<name><surname>Crauste-Manciet</surname><given-names>S</given-names></name>
<name><surname>Hadj-Salah</surname><given-names>E</given-names></name><etal/>
</person-group>. <article-title>Compatibility of parenteral drugs with commercialized total parenteral admixtures: injection of drug inside the admixtures</article-title>. <source>Nutr Clin Metab</source>. <year>2003</year>;<volume>17</volume>:<fpage>8</fpage>-<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr6-0148607112464239">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>MacKay</surname><given-names>M</given-names></name>
<name><surname>Rusho</surname><given-names>W</given-names></name>
<name><surname>Jackson</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Physical and chemical stability of iron sucrose in parenteral nutrition</article-title>. <source>Nutr Clin Pract</source>. <year>2009</year>;<volume>24</volume>:<fpage>733</fpage>-<lpage>737</lpage>.</citation>
</ref>
<ref id="bibr7-0148607112464239">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tounian</surname><given-names>P</given-names></name>
<name><surname>Jehl</surname><given-names>F</given-names></name>
<name><surname>Pauliat</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Stability and compatibility of teicoplanin in parenteral nutrition solutions used in pediatrics</article-title>. <source>Clin Nutr</source>. <year>1999</year>;<volume>18</volume>:<fpage>159</fpage>-<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr8-0148607112464239">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Husson</surname><given-names>E</given-names></name>
<name><surname>Crauste-Manciet</surname><given-names>S</given-names></name>
<name><surname>Hadj-Salah</surname><given-names>E</given-names></name><etal/>
</person-group>. <article-title>Compatibility of parenteral drugs with commercialized total parenteral admixtures during simulated Y-site infusion</article-title>. <source>Nutr Clin Metab</source>. <year>2003</year>;<volume>17</volume>:<fpage>72</fpage>-<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr9-0148607112464239">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trissel</surname><given-names>LA</given-names></name>
<name><surname>Gilbert</surname><given-names>DL</given-names></name>
<name><surname>Martinez</surname><given-names>JF</given-names></name><etal/>
</person-group>. <article-title>Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration</article-title>. <source>Am J Health Syst Pharm</source>. <year>1997</year>;<volume>54</volume>:<fpage>1295</fpage>-<lpage>1300</lpage>.</citation>
</ref>
<ref id="bibr10-0148607112464239">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trissel</surname><given-names>LA</given-names></name>
<name><surname>Gilbert</surname><given-names>DL</given-names></name>
<name><surname>Martinez</surname><given-names>JF</given-names></name><etal/>
</person-group>. <article-title>Compatibility of medications with 3-in-1 parenteral nutrition admixtures</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1999</year>; <volume>23</volume>:<fpage>67</fpage>-<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr11-0148607112464239">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Driscoll</surname><given-names>FF</given-names></name>
<name><surname>Thoma</surname><given-names>A</given-names></name>
<name><surname>Franke</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Lipid globule size in total nutrient admixtures prepared in three-chamber plastic bags</article-title>. <source>Am J Health Syst Pharm</source>. <year>2009</year>;<volume>66</volume>:<fpage>649</fpage>-<lpage>656</lpage>.</citation>
</ref>
<ref id="bibr12-0148607112464239">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Driscoll</surname><given-names>DF</given-names></name>
</person-group>. <article-title>Globule-size distribution in injectable 20% lipid emulsions: compliance with USP requirements</article-title>. <source>Am J Health Syst Pharm</source>. <year>2007</year>;<volume>64</volume>:<fpage>2032</fpage>-<lpage>2036</lpage>.</citation>
</ref>
<ref id="bibr13-0148607112464239">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Driscoll</surname><given-names>DF</given-names></name>
<name><surname>Ling</surname><given-names>PR</given-names></name>
<name><surname>Andersson</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Hepatic indicators of oxidative stress and tissue damage accompanied by systemic inflammation in rats following a 24-hour infusion of an unstable lipid emulsion admixture</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>:<fpage>327</fpage>-<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr14-0148607112464239">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Driscoll</surname><given-names>DF</given-names></name>
<name><surname>Ling</surname><given-names>PR</given-names></name>
<name><surname>Bistrian</surname><given-names>BR</given-names></name>
</person-group>. <article-title>Pathological consequences to reticuloendothelial system organs following infusion of unstable all-in-one mixtures in rats</article-title>. <source>Clin Nutr</source>. <year>2006</year>;<volume>25</volume>:<fpage>842</fpage>-<lpage>850</lpage>.</citation>
</ref>
<ref id="bibr15-0148607112464239">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Driscoll</surname><given-names>DF</given-names></name>
<name><surname>Ling</surname><given-names>PR</given-names></name>
<name><surname>Quist</surname><given-names>WC</given-names></name><etal/>
</person-group>. <article-title>Pathological consequences from the infusion of unstable lipid emulsion admixtures in guinea pigs</article-title>. <source>Clin Nutr</source>. <year>2005</year>;<volume>24</volume>:<fpage>105</fpage>-<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr16-0148607112464239">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Driscoll</surname><given-names>DF</given-names></name>
<name><surname>Ling</surname><given-names>PR</given-names></name>
<name><surname>Silvestri</surname><given-names>AP</given-names></name><etal/>
</person-group>. <article-title>Fine vs. coarse complete all-in-one admixture infusions over 96 hours in rats: fat globule size and hepatic function</article-title>. <source>Clin Nutr</source>. <year>2008</year>;<volume>27</volume>:<fpage>889</fpage>-<lpage>894</lpage>.</citation>
</ref>
<ref id="bibr17-0148607112464239">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ambados</surname><given-names>F</given-names></name>
</person-group>. <article-title>Destabilization of fat emulsion in total nutrient admixtures by concentrated albumin 20% infusions</article-title>. <source>Aust J Hosp Pharm</source>. <year>1999</year>;<volume>29</volume>:<fpage>210</fpage>-<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr18-0148607112464239">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tutunji</surname><given-names>MF</given-names></name>
<name><surname>Qaisi</surname><given-names>AM</given-names></name>
<name><surname>El-Eswed</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>An in vitro investigation on acid catalyzed reactions of proton pump inhibitors in the absence of an electrophile</article-title>. <source>Int J Pharm</source>. <year>2006</year>;<volume>323</volume>:<fpage>110</fpage>-<lpage>116</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>